JP2021533789A5 - - Google Patents
Info
- Publication number
- JP2021533789A5 JP2021533789A5 JP2021507972A JP2021507972A JP2021533789A5 JP 2021533789 A5 JP2021533789 A5 JP 2021533789A5 JP 2021507972 A JP2021507972 A JP 2021507972A JP 2021507972 A JP2021507972 A JP 2021507972A JP 2021533789 A5 JP2021533789 A5 JP 2021533789A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- virus
- disease
- oncolytic
- virus according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718990P | 2018-08-16 | 2018-08-16 | |
| US62/718,990 | 2018-08-16 | ||
| US201862741404P | 2018-10-04 | 2018-10-04 | |
| US62/741,404 | 2018-10-04 | ||
| US201862754622P | 2018-11-02 | 2018-11-02 | |
| US62/754,622 | 2018-11-02 | ||
| US201962813375P | 2019-03-04 | 2019-03-04 | |
| US62/813,375 | 2019-03-04 | ||
| PCT/US2019/046823 WO2020037206A1 (en) | 2018-08-16 | 2019-08-16 | Recombinant myxoma viruses and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533789A JP2021533789A (ja) | 2021-12-09 |
| JP2021533789A5 true JP2021533789A5 (cg-RX-API-DMAC7.html) | 2022-08-22 |
Family
ID=69525939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507972A Pending JP2021533789A (ja) | 2018-08-16 | 2019-08-16 | 組換え粘液腫ウイルスおよびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210196771A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3837354A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021533789A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210094509A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112771157A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019321667A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021002639A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3109216A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL280854A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021001883A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020037206A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100305SA (en) | 2018-07-13 | 2021-02-25 | Univ Arizona State | Methods of treating cancer with tnf expressing myxoma virus |
| US11591616B1 (en) | 2019-04-22 | 2023-02-28 | Colorado State University Research Foundation | Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC |
| WO2021016194A1 (en) | 2019-07-19 | 2021-01-28 | Racaniello Vincent R | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
| CN114615988A (zh) | 2019-09-02 | 2022-06-10 | 亚利桑那州立大学董事会 | 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台 |
| US20240091284A1 (en) * | 2019-10-10 | 2024-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus comprising immunomodulatory transgenes and uses thereof |
| AU2021224730A1 (en) * | 2020-02-20 | 2022-09-22 | Musc Foundation For Research Development | Recombinant myxoma viruses and uses thereof |
| JP2023548746A (ja) | 2020-10-13 | 2023-11-21 | クリヤ セラピューティクス インコーポレイテッド | サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用 |
| WO2022139440A1 (ko) * | 2020-12-22 | 2022-06-30 | 바이로큐어 주식회사 | 신규한 재조합 믹소마바이러스 및 이의 용도 |
| WO2022159508A1 (en) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
| JP2024508920A (ja) * | 2021-03-01 | 2024-02-28 | オンコミクス セラピューティクス,インク. | 多武装の粘液腫ウイルス |
| US20250121017A1 (en) * | 2021-10-29 | 2025-04-17 | Unm Rainforest Innovations | Oncolytic virotherapy compositions and methods |
| KR20240157693A (ko) * | 2022-03-10 | 2024-11-01 | 시티 오브 호프 | 세포 면역요법을 위한 막-결합 il-12 |
| EP4624487A1 (en) * | 2022-11-24 | 2025-10-01 | Tokushima University | Production of antibodies against protein |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2023954B1 (en) * | 2006-05-19 | 2013-07-17 | Sanofi Pasteur, Inc. | Immunological composition |
| WO2008070367A2 (en) * | 2006-11-01 | 2008-06-12 | Facet Biotech Corporation | Mammalian cell-based immunoglobulin display libraries |
| FR2946536B1 (fr) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | Utilisation d'une souche attenuee de myxoma virus comme oncolytique |
| DK3552615T3 (da) * | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| PL3368572T5 (pl) * | 2015-10-02 | 2026-07-20 | Les Laboratoires Servier | Przeciwciała anty-PD-1 oraz kompozycje |
| SI3368683T1 (sl) * | 2015-10-27 | 2020-07-31 | Pharmassist Ltd | Postopek za kvantifikacijo PD-L1 |
| TW201825511A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現免疫檢查點調節子的溶瘤病毒 |
-
2019
- 2019-08-16 BR BR112021002639-8A patent/BR112021002639A2/pt not_active Application Discontinuation
- 2019-08-16 AU AU2019321667A patent/AU2019321667A1/en not_active Abandoned
- 2019-08-16 WO PCT/US2019/046823 patent/WO2020037206A1/en not_active Ceased
- 2019-08-16 MX MX2021001883A patent/MX2021001883A/es unknown
- 2019-08-16 CN CN201980060542.9A patent/CN112771157A/zh active Pending
- 2019-08-16 EP EP19849867.7A patent/EP3837354A4/en not_active Withdrawn
- 2019-08-16 CA CA3109216A patent/CA3109216A1/en active Pending
- 2019-08-16 US US17/268,656 patent/US20210196771A1/en not_active Abandoned
- 2019-08-16 JP JP2021507972A patent/JP2021533789A/ja active Pending
- 2019-08-16 KR KR1020217006855A patent/KR20210094509A/ko not_active Ceased
-
2021
- 2021-02-14 IL IL280854A patent/IL280854A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| O'Bryan et al. | Oncolytic virotherapy for breast cancer treatment | |
| Shi et al. | Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment | |
| Chen et al. | Oncolytic virotherapy in cancer treatment: challenges and optimization prospects | |
| WO2020037206A4 (en) | Recombinant myxoma viruses and uses thereof | |
| JP6794442B2 (ja) | 新規な遺伝子組換えワクシニアウイルス | |
| Dong et al. | Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages | |
| US20220056480A1 (en) | Modified orthopoxvirus vectors | |
| US20240132913A1 (en) | Modified orthopoxvirus vectors | |
| O’Leary et al. | Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose | |
| Li et al. | Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review | |
| BR112019013215A2 (pt) | vírus oncolítico, composição farmacêutica, produto de fabricação, método para tratar câncer e uso | |
| JP2021527694A5 (cg-RX-API-DMAC7.html) | ||
| JP7754891B2 (ja) | Ccl21をコードする組換えラブドウイルス | |
| Chaurasiya et al. | Viroimmunotherapy for breast cancer: Promises, problems and future directions | |
| Huang et al. | Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses | |
| JP2022536929A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510158A (ja) | 抗体組み合わせを用いるウイルス療法 | |
| JP7842751B2 (ja) | 腫瘍溶解性ウイルスが有効なtil療法のためにt細胞応答を強化する | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| WO2020067085A1 (ja) | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 | |
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| Ekeke et al. | Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies: CN Ekeke et al. | |
| TWI817159B (zh) | 重組牛痘病毒 | |
| Akunne et al. | Emerging strategies in cancer immunotherapy: Expanding horizons and future perspectives | |
| JP2023552289A5 (cg-RX-API-DMAC7.html) |